Genesis Capital is pleased to announce that it advised the board of Aptitude Health on its ownership restructuring of TRM Oncology and Axess Oncology to transform it from a holding company into a single new operating business.

“Genesis Capital guided us through a complex process, and continually delivered thoughtful recommendations that led to a positive outcome for the new Aptitude Health”, said Alexei Rojanets, founder and CEO. “With our global portfolio of products and unparalleled access to physicians, we are better positioned to deliver the insights and evidence-based solutions our clients need for the clinical development and commercialization of existing and future oncology products to positively impact patient outcomes.”

At the core of Aptitude Health is the Axess Network of over 500 global scientific thought leaders and more than 1,200 community physicians, making it the leading partner for life sciences companies that need actionable, up-to-the-minute insights on clinical decision-making in oncology and hematology.

Genesis Capital, LLC acted as exclusive financial advisor to Axess Oncology and TRM Oncology while King & Spalding; Smith, Gambrell, & Russell LLP; and NautaDutilh N.V. provided legal counsel.

About Aptitude Health

Aptitude Health provides the world’s leading life sciences companies with unparalleled physician access, business intelligence, medical communication and publication solutions that translate clinical and commercial successes into life-changing cancer treatments. Best-in-class products and services, combined with a proven track record of success, make Aptitude Health the most valued partner for life sciences companies seeking to identify, develop, and commercialize oncology and hematology innovations.